Literature DB >> 21282435

Positive impact of HIV-1 gag cleavage site mutations on the virological response to darunavir boosted with ritonavir.

Lucile Larrouy1, Sidonie Lambert-Niclot, Charlotte Charpentier, Slim Fourati, Benoit Visseaux, Cathia Soulié, Marc Wirden, Christine Katlama, Patrick Yeni, Françoise Brun-Vézinet, Vincent Calvez, Anne-Geneviève Marcelin, Diane Descamps.   

Abstract

We assessed the roles of baseline gag and gag-pol cleavage site mutations (CSM) on the virological outcome of a darunavir-based regimen in highly antiretroviral-experienced patients. We showed the association, in multivariate analysis, between the A431V gag CSM and the virological response, defined as a reduction in plasma HIV-1 RNA to <50 copies/ml at month 3 (P = 0.028). Our results suggest that a specific gag CSM might have a role on protease inhibitor susceptibility in an inhibitor-specific manner.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21282435      PMCID： PMC3067137          DOI： 10.1128/AAC.01049-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  23 in total

1.  Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir.

Authors:  H C Côté; Z L Brumme; P R Harrigan
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

2.  Gag mutations can impact virological response to dual-boosted protease inhibitor combinations in antiretroviral-naïve HIV-infected patients.

Authors:  Lucile Larrouy; C Chazallon; R Landman; C Capitant; G Peytavin; G Collin; C Charpentier; A Storto; G Pialoux; C Katlama; P M Girard; P Yeni; J P Aboulker; F Brun-Vezinet; D Descamps
Journal:  Antimicrob Agents Chemother       Date:  2010-05-03       Impact factor: 5.191

3.  Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors.

Authors:  L Doyon; G Croteau; D Thibeault; F Poulin; L Pilote; D Lamarre
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

4.  Changes in the human immunodeficiency virus p7-p1-p6 gag gene in drug-naive and pretreated patients.

Authors:  Oscar Gallego; Carmen de Mendoza; Angélica Corral; Vincent Soriano
Journal:  J Clin Microbiol       Date:  2003-03       Impact factor: 5.948

5.  Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug.

Authors:  F Mammano; V Trouplin; V Zennou; F Clavel
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

6.  Structural basis for coevolution of a human immunodeficiency virus type 1 nucleocapsid-p1 cleavage site with a V82A drug-resistant mutation in viral protease.

Authors:  Moses Prabu-Jeyabalan; Ellen A Nalivaika; Nancy M King; Celia A Schiffer
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

7.  Overexpression of the HIV-1 gag-pol polyprotein results in intracellular activation of HIV-1 protease and inhibition of assembly and budding of virus-like particles.

Authors:  V Karacostas; E J Wolffe; K Nagashima; M A Gonda; B Moss
Journal:  Virology       Date:  1993-04       Impact factor: 3.616

8.  Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro.

Authors:  Michael F Maguire; Rosario Guinea; Philip Griffin; Sarah Macmanus; Robert C Elston; Josie Wolfram; Naomi Richards; Mary H Hanlon; David J T Porter; Terri Wrin; Neil Parkin; Margaret Tisdale; Eric Furfine; Chris Petropoulos; B Wendy Snowden; Jörg-Peter Kleim
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

9.  Human immunodeficiency virus type 1 gag-pol frameshifting is dependent on downstream mRNA secondary structure: demonstration by expression in vivo.

Authors:  N T Parkin; M Chamorro; H E Varmus
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

10.  Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sites.

Authors:  Anita Fehér; Irene T Weber; Péter Bagossi; Péter Boross; Bhuvaneshwari Mahalingam; John M Louis; Terry D Copeland; Ivan Y Torshin; Robert W Harrison; József Tözsér
Journal:  Eur J Biochem       Date:  2002-08
View more
  5 in total

1.  Comparison of drug resistance scores for tipranavir in protease inhibitor-naive patients infected with HIV-1 B and non-B subtypes.

Authors:  Martin Stürmer; Christoph Stephan; Peter Gute; Gaby Knecht; Markus Bickel; Hans-Reinhard Brodt; Hans W Doerr; Lutz Gürtler; Pierre Lecocq; Margriet van Houtte
Journal:  Antimicrob Agents Chemother       Date:  2011-08-08       Impact factor: 5.191

2.  Novel method for simultaneous quantification of phenotypic resistance to maturation, protease, reverse transcriptase, and integrase HIV inhibitors based on 3'Gag(p2/p7/p1/p6)/PR/RT/INT-recombinant viruses: a useful tool in the multitarget era of antiretroviral therapy.

Authors:  Jan Weber; Ana C Vazquez; Dane Winner; Justine D Rose; Doug Wylie; Ariel M Rhea; Kenneth Henry; Jennifer Pappas; Alison Wright; Nizar Mohamed; Richard Gibson; Benigno Rodriguez; Vicente Soriano; Kevin King; Eric J Arts; Paul D Olivo; Miguel E Quiñones-Mateu
Journal:  Antimicrob Agents Chemother       Date:  2011-05-31       Impact factor: 5.191

3.  Modulation of HIV-1 Gag/Gag-Pol frameshifting by tRNA abundance.

Authors:  Natalia Korniy; Akanksha Goyal; Markus Hoffmann; Ekaterina Samatova; Frank Peske; Stefan Pöhlmann; Marina V Rodnina
Journal:  Nucleic Acids Res       Date:  2019-06-04       Impact factor: 16.971

Review 4.  Human Immunodeficiency Virus Gag and protease: partners in resistance.

Authors:  Axel Fun; Annemarie M J Wensing; Jens Verheyen; Monique Nijhuis
Journal:  Retrovirology       Date:  2012-08-06       Impact factor: 4.602

5.  Resistance mutations outside the integrase coding region have an effect on human immunodeficiency virus replicative fitness but do not affect its susceptibility to integrase strand transfer inhibitors.

Authors:  Jan Weber; Justine D Rose; Ana C Vazquez; Dane Winner; Nicolas Margot; Damian J McColl; Michael D Miller; Miguel E Quiñones-Mateu
Journal:  PLoS One       Date:  2013-06-11       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.